- Conditions
- Arthritis, Rheumatoid Arthritis
- Interventions
- CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate
- Biological · Other · Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma, Healthy Subjects or Volunteers
- Interventions
- Tralokinumab 300 mg
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Lincoln, Nebraska
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose)
- Biological · Drug
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • Nashville, Tennessee + 1 more
- Conditions
- Polypharmacy, Dementia, Multiple Chronic Conditions, Deprescribing, Mild Cognitive Impairment
- Interventions
- Educational Materials
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Reading, Pennsylvania
- Conditions
- B-ALL, Hematologic Malignancy, Solid Tumor
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 4 more
- Conditions
- Erosive Esophagitis
- Interventions
- H008, H008 placebo, Lansoprazole
- Drug
- Lead sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Efavaleukin Alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more
- Conditions
- Human Metapneumovirus Infection
- Interventions
- AZD0543, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Los Alamitos, California • South Miami, Florida
- Conditions
- Solid Tumor, Extensive-stage Small Cell Lung Cancer
- Interventions
- BNT411, Atezolizumab, Carboplatin, Etoposide
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Chicago, Illinois • Greenville, South Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Anaheim, California + 49 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- Vesatolimod, Cobicistat, Voriconazole, Rifabutin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- AEF0117, Placebo
- Drug
- Lead sponsor
- Aelis Farma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Pompe Disease
- Interventions
- VAL-1221, RhGAA
- Drug
- Lead sponsor
- Valerion Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Orange, California • Durham, North Carolina
- Conditions
- Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
- Interventions
- Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance]
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 10
- States / cities
- Santa Monica, California • Atlanta, Georgia • Chicago, Illinois + 6 more
- Conditions
- Obesity
- Interventions
- NO-13065, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Solid Tumors, Merkel Cell Carcinoma
- Interventions
- FF-10850 Topotecan Liposome Injection
- Drug
- Lead sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more
- Conditions
- Healthy Lactating Women
- Interventions
- SPN-812 (600mg, QD)
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Urothelial Carcinoma, Locally Advanced, Unresectable
- Interventions
- Atezolizumab, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 9
- States / cities
- Chicago, Ill • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
- Conditions
- Solid Tumors, Metastatic Tumors
- Interventions
- OTS167IV
- Drug
- Lead sponsor
- OncoTherapy Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Dental Caries
- Interventions
- C16G2, Placebo
- Drug · Other
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Treprostinil sodium for inhalation
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
- Conditions
- Healthy
- Interventions
- LY3985297, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Anaheim, California • Salt Lake City, Utah
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Orange, California • Santa Monica, California • Chicago, Illinois + 8 more